Veale D J, Reece R J, Parsons W, Radjenovic A, O'Connor P J, Orgles C S, Berry E, Ridgway J P, Mason U, Boylston A W, Gibbon W, Emery P
Rheumatology and Rehabilitation Research Unit, Leeds SmithKline Beecham Pharmaceuticals, Leeds LS3 9NZ, United Kingdom.
Ann Rheum Dis. 1999 Jun;58(6):342-9. doi: 10.1136/ard.58.6.342.
CD4+ T cells sustain the chronic synovial inflammatory response in rheumatoid arthritis (RA). SB-210396/CE 9.1 is an anti-CD4 monoclonal antibody that has documented efficacy in RA when given intravenously. This study aimed to establish the safety and efficacy of the intra-articular administration of SB-210396/CE 9.1 compared with placebo, examining its mode of action using a combined imaging approach of arthroscopy, magnetic resonance imaging (MRI), and histology.
Thirteen RA patients with active, resistant knee synovitis, were randomised to intra-articular injection of placebo (n=3), 0.4 mg (n=3) or 40 mg (n=7) of anti-CD4 after sequential dynamic gadolinium enhanced MRI, followed by same day arthroscopy and synovial membrane biopsy. Imaging and arthroscopic synovial membrane sampling were repeated at six weeks. This study used a unique region of interest (ROI) analysis mapping the MRI area analysed to the specific biopsy site identified arthroscopically, thus providing data for all three modalities at the same synovial membrane site.
12 patients completed the study (one placebo treated patient refused further MRI). Arthroscopic improvement was observed in 0 of 2 placebo patients but in 10 of 10 patients receiving active drug (>20% in 6 of 10). Improvement in MRI was consistently observed in all patients of the 40 mg group but not in the other two groups. A reduction in SM CD4+ score was noted in the 40 mg group and in the 0.4 mg group. Strong correlations both before and after treatment, were identified between the three imaging modalities. Intra-articular delivery of SB-210396/CE 9.1 was well tolerated.
SB-210396/CE 9.1 is safe when administered by intra-articular injection. A trend toward efficacy was found by coordinated MRI, arthroscopic, and histological imaging, not seen in the placebo group. The value of ROI analysis was demonstrated.
CD4 + T细胞维持类风湿关节炎(RA)的慢性滑膜炎症反应。SB - 210396/CE 9.1是一种抗CD4单克隆抗体,静脉注射时已证明对RA有效。本研究旨在确定与安慰剂相比,关节腔内注射SB - 210396/CE 9.1的安全性和有效性,并使用关节镜检查、磁共振成像(MRI)和组织学的联合成像方法研究其作用方式。
13例患有活动性、难治性膝关节滑膜炎的RA患者,在进行连续动态钆增强MRI后,随机接受关节腔内注射安慰剂(n = 3)、0.4 mg(n = 3)或40 mg(n = 7)抗CD4药物,随后在同一天进行关节镜检查和滑膜活检。在六周时重复进行成像和关节镜滑膜取样。本研究使用了一个独特的感兴趣区域(ROI)分析,将MRI分析区域映射到通过关节镜确定的特定活检部位,从而在同一滑膜部位提供所有三种模式的数据。
12例患者完成了研究(1例接受安慰剂治疗的患者拒绝进一步的MRI检查)。2例接受安慰剂治疗的患者中0例关节镜检查有改善,但接受活性药物治疗的10例患者中有10例改善(10例中有6例改善>20%)。40 mg组的所有患者均持续观察到MRI改善,而其他两组未观察到。40 mg组和0.4 mg组的SM CD4 +评分降低。治疗前后,三种成像模式之间均发现有强相关性。关节腔内注射SB - 210396/CE 9.1耐受性良好。
关节腔内注射SB - 210396/CE 9.1是安全的。通过协调的MRI、关节镜和组织学成像发现了一种疗效趋势,而安慰剂组未观察到。证明了ROI分析的价值。